Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2020 Jan;19(1):89–100. doi: 10.1158/1535-7163.MCT-19-0205

Figure 6. Verticillin A reduces tumor burden in vivo.

Figure 6.

(A) OVCAR8-RFP cells were xenografted IP to form tumors. Mice were dosed with eNP-VA and eNP once every 2 days for total 12 days (Dosage: 0.5 mg/kg). Representative images show IVIS images of tumors in mice on Day 0, 4, 8 and 12 of drug treatment. (B) Quantification of tumor burden (average radiant efficiency as measured with IVIS imaging) normalized to Day 0. Statistics were performed using two-way ANOVA relative to vehicle control. (C) Quantification of average bodyweight of the mice during the course of treatment with eNP and eNP-VA. (D) H&E staining showing the histomorphology of paraffin embedded tumor tissue sections of eNP and eNP-VA treated animals. (E) Immunohistochemistry of γH2A.X and cPARP staining as markers of DNA damage and apoptosis is shown from tumors of animals treated with eNP and eNP-VA. Scale bar: 20 μm.